Vaccination with recombinant Mycoplasma bovis GAPDH results in a strong humoral immune response but does not protect feedlot cattle from an experimental challenge with M. bovis

Microbial Pathogenesis

Volumn 55, Issue 1, 2013, Pages 1-8

  Prysliak, Tracy ^a   van der Merwe, Jacques ^b   Perez Casal, Jose ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cattle; GAPDH; Mycoplasma bovis; Vaccines

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; PLASMID VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIUM ISOLATE; CATTLE; CELLULAR IMMUNITY; CHIMERA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HOST PATHOGEN INTERACTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; LUNG LESION; MYCOPLASMA BOVIS; MYCOPLASMOSIS; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RECOMBINANT GENE; RECTUM TEMPERATURE; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CATTLE; CATTLE DISEASES; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; IMMUNITY, HUMORAL; MALE; MYCOPLASMA BOVIS; MYCOPLASMA INFECTIONS; VACCINATION;

ANIMALIA; BOS; MYCOPLASMA BOVIS;

EID: 84871901908     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.12.001     Document Type: Article

References (39)

1. Nicholas R.A., Ayling R.D. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci 2003, 74(2):105-112.
2. van der Merwe J., Prysliak T., Perez-Casal J. Invasion of bovine peripheral-blood mononuclear cells and erythrocytes by Mycoplasma bovis. Infect Immun 2010, 78(11):4570-4578.
3. Chima J.C., Wilkie B.N., Ruhnke H.L., Truscott R.B., Curtis R.A. Immunoprophylaxis of experimental Mycoplasma bovis arthritis in calves. Protective efficacy of live organisms and formalinized vaccines. Vet Microbiol 1980, 5:113-122.
4. Howard C.J., Stott E.J., Thomas L.H., Gourlay R.N., Taylor G. Protection against respiratory disease in calves induced by vaccines containing respiratory syncytial virus, parainfluenza type 3 virus, Mycoplasma bovis and M. dispar. Vet Rec 1987, 121(16):372-376.
5. Maunsell F.P., Donovan G.A., Risco C., Brown M.B. Field evaluation of a Mycoplasma bovis bacterin in young dairy calves. Vaccine 2009, 27(21):2781-2788.
6. Nicholas R.A., Ayling R.D., Stipkovits L.P. An experimental vaccine for calf pneumonia caused by Mycoplasma bovis: clinical, cultural, serological and pathological findings. Vaccine 2002, 20(29-30):3569-3575.
7. Maunsell F.P., Woolums A.R., Francoz D., Rosenbusch R.F., Step D.L., Wilson D.J., et al. Mycoplasma bovis infections in cattle. J Vet Intern Med 2011, 25(4):772-783.
8. Sachse K., Helbig J.H., Lysnyansky I., Grajetzki C., Muller W., Jacobs E., et al. Epitope mapping of immunogenic and adhesive structures in repetitive domains of Mycoplasma bovis variable surface lipoproteins. Infect Immun 2000, 68(2):680-687.
9. Sachse K., Pfutzner H., Heller M., Hanel I. Inhibition of Mycoplasma bovis cytadherence by a monoclonal antibody and various carbohydrate substances. Vet Microbiol 1993, 36(3-4):307-316.
10. Robino P., Alberti A., Pittau M., Chessa B., Miciletta M., Nebbia P., et al. Genetic and antigenic characterization of the surface lipoprotein P48 of Mycoplasma bovis. Vet Microbiol 2005, 109(3-4):201-209.
11. Scherm B., Gerlach G.F., Runge M. Analysis of heat shock protein 60 encoding genes of mycoplasmas and investigations concerning their role in immunity and infection. Vet Microbiol 2002, 89(2-3):141-150.
12. Boel G., Jin H., Pancholi V. Inhibition of cell surface export of group A streptococcal anchorless surface dehydrogenase affects bacterial adherence and antiphagocytic properties. Infect Immun 2005, 73(10):6237-6248.
13. Kinoshita H., Uchida H., Kawai Y., Kawasaki T., Wakahara N., Matsuo H., et al. Cell surface Lactobacillus plantarum LA 318 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) adheres to human colonic mucin. J Appl Microbiol 2008, 104(6):1667-1674.
14. Kinoshita H., Wakahara N., Watanabe M., Kawasaki T., Matsuo H., Kawai Y., et al. Cell surface glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of Lactobacillus plantarum LA 318 recognizes human A and B blood group antigens. Res Microbiol 2008, 159(9-10):685-691.
15. Lama A., Kucknoor A., Mundodi V., Alderete J.F. Glyceraldehyde-3-Phosphate dehydrogenase is a surface-associated, fibronectin-binding protein of Trichomonas vaginalis. Infect Immun 2009, 77(7):2703-2711.
16. Maeda K., Nagata H., Kuboniwa M., Kataoka K., Nishida N., Tanaka M., et al. Characterization of binding of Streptococcus oralis glyceraldehyde-3-phosphate dehydrogenase to Porphyromonas gingivalis major fimbriae. Infect Immun 2004, 72(9):5475-5477.
17. Jin H., Song Y.P., Boel G., Kochar J., Pancholi V. Group A streptococcal surface GAPDH, SDH, recognizes uPAR/CD87 as its receptor on the human pharyngeal cell and mediates bacterial adherence to host cells. J Mol Biol 2005, 350(1):27-41.
18. Kerro-Dego O., Prysliak T., Perez-Casal J., Potter A.A. Role of GapC in the pathogenesis of Staphylococcus aureus. Vet Microbiol 2012, 156(3-4):443-447.
19. Purves J., Cockayne A., Moody P.C., Morrissey J.A. Comparison of the regulation, metabolic functions, and roles in virulence of the glyceraldehyde-3-phosphate dehydrogenase homologues gapA and gapB in Staphylococcus aureus. Infect Immun 2010, 78(12):5223-5232.
20. Terao Y., Yamaguchi M., Hamada S., Kawabata S. Multifunctional glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential for evasion from neutrophils. J Biol Chem 2006, 281(20):14215-14223.
21. Hoelzle K., Doser S., Ritzmann M., Heinritzi K., Palzer A., Elicker S., et al. Vaccination with the M. suis recombinant adhesion protein MSG1 elicits a strong immune response but fails to induce protection in pigs. Vaccine 2009, 27(39):5376-5382.
22. Fontaine M.C., Perez-Casal J., Song X.M., Shelford J., Willson P.J., Potter A.A. Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge. Vaccine 2002, 20(17-18):2278-2286.
23. Bolton A., Song X.M., Willson P., Fontaine M.C., Potter A.A., Perez-Casal J. Use of the surface proteins GapC and Mig of Streptococcus dysgalactiae as potential protective antigens against bovine mastitis. Can J Microbiol 2004, 50(6):423-432.
24. Perez-Casal J., Prysliak T. Detection of antibodies against the Mycoplasma bovis glyceraldehyde-3-phosphate dehydrogenase protein in beef cattle. Microb Pathog 2007, 43(5-6):189-197.
25. Bowdish D.M., Davidson D.J., Scott M.G., Hancock R.E. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005, 49(5):1727-1732.
26. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 2000, 19(6):618-622.
27. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, et al. Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines;10(1):95-107.
28. van der Merwe J., Prysliak T., Gerdts V., Perez-Casal J. Protein chimeras containing the Mycoplasma bovis GAPDH protein and bovine host-defence peptides retain the properties of the individual components. Microb Pathog 2011, 50(6):269-277.
29. Vordermeier H.M., Pontarollo R., Karvonen B., Cockle P., Hecker R., Singh M., et al. Synthetic peptide vaccination in cattle: induction of strong cellular immune responses against peptides derived from the Mycobacterium bovis antigen Rv3019c. Vaccine 2005, 23(35):4375-4384.
30. Prysliak T., Van der Merwe J., Lawman Z., Wilson D., Townsend H., van Drunen Littel-van den Hurk S., et al. Respiratory disease caused by Mycoplasma bovis is enhanced by exposure to bovine herpes virus 1 (BHV-1) and not to bovine viral diarrhoea virus (BVDV) type 2. Can Vet J 2011, 52:1195-1202.
31. Pontarollo R.A., Babiuk L.A., Hecker R., Van Drunen Littel-Van Den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 2002, 83(Pt 12):2973-2981.
32. Lingnau K., Egyed A., Schellack C., Mattner F., Buschle M., Schmidt W. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 2002, 20(29-30):3498-3508.
33. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24(26):5461-5472.
34. Boothby J.T., Jasper D.E., Thomas C.B. Experimental intramammary inoculation with Mycoplasma bovis in vaccinated and unvaccinated cows: effect on local and systemic antibody response. Can J Vet Res 1987, 51(1):121-125. Revue canadienne de recherche veterinaire.
35. Vanden Bush T.J., Rosenbusch R.F. Characterization of the immune response to Mycoplasma bovis lung infection. Vet Immunol Immunopathol 2003, 94(1-2):23-33.
36. Thomas C.B., Mettler J., Sharp P., Jensen-Kostenbader J., Schultz R.D. Mycoplasma bovis suppression of bovine lymphocyte response to phytohemagglutinin. Vet Immunol Immunopathol 1990, 26(2):143-155.
37. Vanden Bush T.J., Rosenbusch R.F. Characterization of a lympho-inhibitory peptide produced by Mycoplasma bovis. Biochem Biophys Res Commun 2004, 315(2):336-341.
38. Nicholas R., Tjipura-Zaire G., Mbulu R.S., Scacchia M., Mettler F., Frey J., et al. An inactivated whole cell vaccine and LppQ subunit vaccine appear to exacerbate the effects of CBPP in adult cattle 2003, FAO-OIE-OAU/IBAR-IAEA Consultative Group on CBPP, Rome, Italy, p. 91-7.
39. Mulongo M.M. Evaluation of lipoprotein Q and L-α-glycerol-3-phosphate oxidase of Mycoplasma mycoides subsp. mycoides (small colony) in contagious bovine pleuropneumonia (CBPP) infections 2011, University of London, London. UK.